



Biotechnology Experts Join Phyllom BioProducts' Business Advisory Board and Take On Expanded Roles

Oakland, Calif., September 1st, 2017 — Phyllom BioProducts Corp., the horticulture industry's innovation leader in microbial insect control, announced appointments of John McIntyre Ph.D. and Walter Funk Ph.D. to its Business Advisory Board and Head of Production, respectively.



John L. McIntyre, Ph.D. has led a long and storied career in the Biotech Industry: primarily focused on building companies, novel technologies and products in the Agriculture Sector. Currently, John is President of Life Science Advisors, a consulting firm to a diversity of life science companies, including Phyllom BioProducts, regarding business development, financing, staffing, product development and market introduction strategies. Prior to that John was President and Chief Executive Officer and a Director of Vestaron Corporation (formerly Venomix, Inc.). As an Officer of Vestaron he has successfully raised cash, met corporate milestones, established corporate partnerships and received competitive State of Michigan investments. Prior to joining Vestaron he was President and CEO and a Director of Emerald BioAgriculture Corporation. Dr. McIntyre has significant experience in raising venture and corporate capital to support successful development, registration and market introduction of specialty agricultural products. Dr. McIntyre has led companies from the research and development stage to successful commercial ventures with product sales on diverse crops in both domestic and international markets. John also held senior management positions with Ecogen Inc., an agricultural biotechnology company developing and marketing specialty biorational pesticide products. John has over 40 years' experience in agricultural biotechnology and has significant operational experience in the development and commercialization of specialty agricultural products.

John led the project that resulted in the first registration by the United States Environmental Protection Agency (EPA) of a biological fungicide. He also led discussions with the EPA that resulted in the first environmental release of a genetically altered microbe without an Experimental Use Permit and its subsequent registration by the EPA.

With Ecogen he established a successful international network of distributors in Europe and Asia. He also led the Company's M&A activities that resulted in the acquisition and assimilation of three companies. John also negotiated key business contracts and licenses in support of the

Company's development and commercial activities, including being active in the Company's Initial Public Offering and subsequent public and private placements and an off-balance sheet financing.

At Emerald Bio, John raised venture capital to support successful development, registration, and commercialization of novel agricultural products. He led the company through research and development phases to a successful company with product sales on diverse crops in domestic and international markets. He also led the successful merger between Auxein Corporation and Mycotech Corporation to result in Emerald BioAgriculture Corporation, an agricultural biotechnology company with a diverse product portfolio.

John Libs, Phyllom's Chief Executive Officer, commented, "Phyllom is pleased that such an experienced and successful entrepreneur such as Dr. McIntyre has join our Business Advisory Board as we continue to build out our Team and broaden and ramp our product sales and other commercial activities. John is a tremendous asset in our quest to reach our business goals"



Walter Funk, Ph.D. is an experienced biotech professional, having held both senior technical and executive research positions over the past 25 years. Dr. Funk has recently expanded his role beyond his Board of Directors Position at Phyllom to become more involved in the day-to-day operations with an emphasis on production and supply chain.

He was trained in Biochemistry (Ph.D., University of British Columbia) and has published over 40 peer-reviewed journal articles (Science, PNAS, J. Mol. Biol). He was a founding scientist at Geron, a NASDAQ-listed biotech company, where he helped develop important telomerase-related technologies that allow for the convenient immortalization of human cell lines. Later at Geron, he worked with the world's first human embryonic stem cell lines and provided the first detailed description of their gene expression systems.

Dr. Funk held the position of V.P. Research at Nuvelo, Inc., where he led a staff of 50 developing novel human biotherapeutics. His group identified R-spondin proteins, an important new class of human growth factors which are now entering into clinical trials and also developed effective new antibodies for the treatment of human malignancies. Dr. Funk co-founded Parallax Venture Partners, a seed-stage capital group that has made investments in the areas of biotech/medical devices.

Most recently, Dr Funk joined BioTime, Inc. as VP of Stem Cell Research. He sits on the Scientific Advisory Board of BioMarkers, a biotherapeutic start up developing natural source medicines, and is on the Executive Board of Gene Oracle, a leading provider of synthetic gene technologies and services.

John Libs, Phyllom's Chief Executive Officer, commented, "Walter has answered the call to help push our company towards success as he takes on the crucial role of managing the front part of our production chain. His technical and management expertise has been invaluable to get

Phyllom on the right track to produce and supply our products to fill an ever increasing market demand.”

About Phyllom BioProducts Corp.

484 Lake Park Ave # 23 • Oakland, CA 94610 • 650-322-5000

Phyllom BioProducts Corp. (Phyllom) discovers, develops and markets novel insect controls with low eco impact that protect the beauty, health and value of forests, farms and landscapes from devastation by beetle, weevil and grub invaders. Phyllom is now in launch stage with its brands beetleGONE!®, grubGONE!® and boreGONE!®. This suite of proprietary products and technologies are protected by a number of issued and pending patents. For more information about Phyllom, please go to www.PhyllomBioProducts.com

For inquiries contact:

Phyllom BioProducts

John Libs

Tel. 1.650.296.2574

johnlibs@phyllom.com